Pierre Legrain left Hybrigenics on June 20 to head the department of biology at Commissariat à l’ Energie Atomique, the French Atomic Energy Commission, in Saclay, France. He was Hybrigenics’ chief technology officer. “It’s directly linked to the evolution of the company, since we are evolving from a platform technology company to a drug discovery company,” said Hybrigenics’ CEO Donny Strosberg.
Thomas McNaughton, formerly vice-president of legal affairs at Aclara Biosciences, has been appointed vice president of intellectual property at Hayward, Calif.-based Zyomyx. John Lewis, formerly vice-president of customer development at BD Biosciences Clontech, has become the company’s vice president of sales and marketing. McNaughton holds a BS in science and engineering from the US Military Academy at West Point and a JD from the University of Michigan. Lewis, who also previously worked as director of product sales for Celera Genomics, received his BS in zoology from the University of Florida. Meanwhile, Hirday Bhathal, vice president of corporate development, is leaving Zyomyx.
Aileen Alvarado-Swaisgood has become the Western regional sales manager of Nonlinear USA, a subsidiary of Newcastle upon Tyne, UK-based Nonlinear Dynamics. She will market proteomics software in the western US. Alvarado-Swaisgood spent the past ten years as a sales manager at Accelrys.
Michael Courtney has become chairman and CEO of Aptanomics of Lyon, France. Previously, he was COO of Noxxon Pharma; before that he was CSO of Transgene. Courtney holds a PhD from the University of London and a BS from the University of Glasgow.